Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 3/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.40 |
| ▸ | BCR | P11274 | 3/20 | 0.40 |
| ▸ | QDPR | P09417 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795678 | 0.81 | TNKS2 (0.37) | MEN1KMT2AQDPR | |
| SCHEMBL18000465 | 0.80 | SLC22A2 (0.46) | ALOX5 | |
| SCHEMBL4099241 | 0.78 | DYRK1A (0.46) | ESR2MEN1KMT2AHSD17B1HSD17B2 | |
| SCHEMBL14290950 | 0.77 | KIF11 (0.42) | — | |
| SCHEMBL4098494 | 0.72 | ESR1 (0.58) | ESR1ESR2MEN1KMT2AALOX5 | |
| Bromide SCHEMBL4084219 | 0.70 | ESR1 (0.55) | ESR1ESR2MEN1KMT2AALOX5 | |
| SCHEMBL9747522 | 0.66 | — | — | |
| SCHEMBL12954736 | 0.66 | ESR1 (0.55) | ESR1ESR2MEN1KMT2AALOX5 | |
| SCHEMBL9090705 | 0.65 | ESR1 (1.00) | ESR1ESR2MEN1KMT2AALOX5 | |
| SCHEMBL15632 | 0.65 | ESR1 (1.00) | ESR1ESR2MEN1KMT2AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874746-B1 | DERIVATIVES OF 1-N-AZACYCLOALKYL-3-PHENOXYPROPANE USEFUL FOR THE PREPARATION OF PSYCHOTROPIC MEDICAMENTS | BIOPROJET SOC CIV (FR) | 2015-11-18 | — | — | EP | disclosed |
| CN-101258138-B | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3-receptor ligands | BIOPROJET SOC CIV | 2013-06-12 | — | — | CN | disclosed |
| US-8076329-B2 | Histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2011-12-13 | — | — | US | disclosed |
| US-8076329-B2 | Histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2009-04-30 | — | — | US | disclosed |
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2009-04-30 | — | — | US | disclosed |
| CN-101258138-A | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3-receptor ligands | BIOPROJET SOC CIV (FR) | 2008-09-03 | — | — | CN | disclosed |
| EP-1874746-A2 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117609-A2 | PHENOXYPROPYLPIPERIDINES AND -PYRROLIDINES AND THEIR USE AS HISTAMINE H3 -RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH1 | ESR1 645/4885ESR2 597/4885MEN1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.